Experienced in Post-Traumatic Epilepsy

Jie M. Zhong

No. 197, Ruijin 2nd Rd, 
Shanghai, CN 
Experienced in Post-Traumatic Epilepsy
No. 197, Ruijin 2nd Rd, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Jie Zhong practices in Shanghai, China. Zhong is rated as an Experienced expert by MediFind in the treatment of Post-Traumatic Epilepsy. Their top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Colitis, Vitrectomy, and Endoscopy.

Their clinical research consists of co-authoring 460 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Post-Traumatic Epilepsy.

Locations

No. 197, Ruijin 2nd Rd, Shanghai, 200025, China
Other Locations
1665, Kong Jiang Road, Shanghai, 200092, China
Union Hospital, Wuhan, 430022, China
197 Ruijin 2nd Road, Shanghai, 200025, China
No. 32 West Second Section First Ring Road, Chengdu, China
26 Shengli Street, Wuhan, 430014, China
Shanghai Jiaotong University No. 197 Ruijin Second Road, Huangpu, 200025, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-World Clinical Practice in China
A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-World Clinical Practice in China
Enrollment Status: Completed
Publish Date: July 22, 2024
Assessment of Equivalence of a Non-invasive In-vitro Diagnostic Test (Peptest) in Comparison to Other Routine Clinical Diagnostic Methods for GERD by Testing a Large Number of Clinical Samples
Assessment of Equivalence of a Non-invasive In-vitro Diagnostic Test (Peptest) in Comparison to Other Routine Clinical Diagnostic Methods for GERD by Testing a Large Number of Clinical Samples
Enrollment Status: Completed
Publish Date: December 08, 2017
Intervention Type: Other
View 5 Less Clinical Trials

460 Total Publications

Short tandem repeats in populations of the Qinghai-Tibet Plateau and adjacent regions provide insights into high-altitude adaptation.
Short tandem repeats in populations of the Qinghai-Tibet Plateau and adjacent regions provide insights into high-altitude adaptation.
Journal: Science advances
Published: October 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhong's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 60 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile